Available on Android and to be subsequently rolled out on iOS devices, CipAir is a free tool accessible through the Breathefree mobile application, Cipla’s existing patient support ecosystem for respiratory care
Cipla has announced the launch of CipAir, a mobile application designed to enable timely and convenient first line of screening for asthma in India. This technology is clinically validated through a multi-centric pan-India study. It aims to empower people by helping them understand their likelihood of an asthma diagnosis thereby allowing them to seek timely intervention and management in case of such indications.
Available on Android and to be subsequently rolled out on iOS devices, CipAir is a free tool accessible through the Breathefree mobile application, Cipla’s existing patient support ecosystem for respiratory care. Through its proprietary algorithm and software, it transforms one’s mobile phone into an asthma screening device using detailed acoustic signature analysis coupled with artificial neural network science. When performed in quiet surroundings as directed by the tool, in less than a minute, through three guided exhalations into the handset, the tool produces a personalised result that indicates the presence, absence or likely future onset of asthma, and guides people to appropriate action basis the findings. Users are further equipped with access to vital knowledge resources pertaining to lung health and qualified experts via Cipla’s extensive Breathefree platform.
Umang Vohra, Managing Director & Global CEO, Cipla said, “At Cipla, our approach to healthcare is deeply rooted in innovation. By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes. Patient-centricity is at the heart of what we do, and CipAir’s AI-led technology is yet another step forward in making personalised healthcare accessible and user-friendly, thereby empowering them to live fuller lives.”
Commenting on this latest technology, Achin Gupta, CEO, One India Business, Cipla, said, “CipAir is a powerful clinically validated tool that puts health in the hands of patients and enables timely intervention against asthma so that they don’t have to compromise on their quality of life. As lung leaders, it is our firm resolve to help India tackle its growing asthma burden and breathe free through such cutting-edge solutions that strengthen the asthma care ecosystem.”